Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgitte Vrou Offersen

Showing results (21-30 of 73) with videos related to

Pageof 8
Sort By:
Acta Oncologica (Stockholm, Sweden)|November 4, 2020
Patient-reported outcomes in postmenopausal breast cancer survivors - comparisons with normative dataAnders Winther Mølby Nielsen, Morten Horsholt Kristensen, Birgitte Vrou Offersen, et al.
Acta Oncologica (Stockholm, Sweden)|September 28, 2021
Symptom trajectories in breast cancer survivors: growth mixture analysis of patient-reported pain, fatigue, insomnia, breast and arm symptomsAnders Winther Mølby Nielsen, Marie Lundorff, Hanne Melgaard Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|September 26, 2023
Diagnosis and treatment of breast cancer in Denmark during the COVID-19 pandemic: a nationwide population-based studyElse Helene Ibfelt, Henry Jensen, Birgitte Vrou Offersen, et al.
The American Journal of Pathology|October 28, 2003
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomasBirgitte Vrou Offersen, Boye Schnack Nielsen, Gunilla Høyer-Hansen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 15, 2022
Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trialMarie Overgaard, Hanne Melgaard Nielsen, Trine Tramm, et al.
Acta Oncologica (Stockholm, Sweden)|December 6, 2017
Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaborationBent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, et al.
Breast (Edinburgh, Scotland)|July 9, 2025
Prognostic value of tumor-infiltrating lymphocytes in irradiated node-positive breast cancer patientsDemet Özcan, Anders Winther Mølby Nielsen, Jan Alsner, et al.
Annals of Surgical Oncology|May 12, 2020
Residual Glandular Breast Tissue After Mastectomy: A Systematic ReviewOrit Kaidar-Person, Liesbeth J Boersma, Philip Poortmans, et al.
Ugeskrift for Laeger|October 5, 2016
[Cardiovascular complications following thoracic radiotherapy in patients with cancer]Kirsten Melgaard Nielsen, Julie I Helene Borchsenius, Birgitte Vrou Offersen, et al.
Acta Oncologica (Stockholm, Sweden)|May 10, 2008
A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancerBirgitte Vrou Offersen, Jan Alsner, Karen Ege Olsen, et al.
Pageof 8

Showing results (21-30 of 73) with videos related to

Sort By:
Pageof 8
Acta Oncologica (Stockholm, Sweden)|November 4, 2020
Patient-reported outcomes in postmenopausal breast cancer survivors - comparisons with normative dataAnders Winther Mølby Nielsen, Morten Horsholt Kristensen, Birgitte Vrou Offersen, et al.
Acta Oncologica (Stockholm, Sweden)|September 28, 2021
Symptom trajectories in breast cancer survivors: growth mixture analysis of patient-reported pain, fatigue, insomnia, breast and arm symptomsAnders Winther Mølby Nielsen, Marie Lundorff, Hanne Melgaard Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|September 26, 2023
Diagnosis and treatment of breast cancer in Denmark during the COVID-19 pandemic: a nationwide population-based studyElse Helene Ibfelt, Henry Jensen, Birgitte Vrou Offersen, et al.
The American Journal of Pathology|October 28, 2003
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomasBirgitte Vrou Offersen, Boye Schnack Nielsen, Gunilla Høyer-Hansen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 15, 2022
Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trialMarie Overgaard, Hanne Melgaard Nielsen, Trine Tramm, et al.
Acta Oncologica (Stockholm, Sweden)|December 6, 2017
Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaborationBent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, et al.
Breast (Edinburgh, Scotland)|July 9, 2025
Prognostic value of tumor-infiltrating lymphocytes in irradiated node-positive breast cancer patientsDemet Özcan, Anders Winther Mølby Nielsen, Jan Alsner, et al.
Annals of Surgical Oncology|May 12, 2020
Residual Glandular Breast Tissue After Mastectomy: A Systematic ReviewOrit Kaidar-Person, Liesbeth J Boersma, Philip Poortmans, et al.
Ugeskrift for Laeger|October 5, 2016
[Cardiovascular complications following thoracic radiotherapy in patients with cancer]Kirsten Melgaard Nielsen, Julie I Helene Borchsenius, Birgitte Vrou Offersen, et al.
Acta Oncologica (Stockholm, Sweden)|May 10, 2008
A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancerBirgitte Vrou Offersen, Jan Alsner, Karen Ege Olsen, et al.
Pageof 8